Overview

Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative Colitis

Status:
Recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the PK, safety and tolerability of cobitolimod ememas (500mg/50mL) given to participants with active left-sided UC.
Phase:
Phase 1
Details
Lead Sponsor:
InDex Pharmaceuticals